Abstract
Urinary polyamine was measured using an enzyme assay in 53 patients with breast cancer, and its clinical significance was evaluated. The mean polyamine level of 168 normal subjects was 48.2 μmol/g cr, and those exceeding this level were judged to be positive. The positive rate in breast cancer patients was significantly greater than that in patients with benign breast diseases and normal subjects (p<0.01). The diagnostic accuracy of polyamine was higher than that of traditional tumor markers such as TPA, CEA and CA15-3, and the accuracy further improved in combination with TPA. Along with the advancement of cancer staging, both mean level and positive rate of polyamine increased, and a paticularly marked increase was noted in cancer recurrence and in cancers with metastases. In relation to therapy, polyamine levels returned to the normal value at one month following operation and at two months after starting chemotherapy, when these therapeutic methods were effective. The measurement of urinary polyamine by enzyme assay is simple to perform. From the present study, it is suggested that this diagnostic test is valuable in detecting recurrence and metastasis, in postoperative follow-up, and in determining the effect of various therapies in patients with breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The journal of the Japanese Practical Surgeon Society
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
